News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Dose reduction does not limit efficacy of trastuzumab deruxtecan in MBC
01 Oct 2025
byStephen Padilla
Reducing the dose of trastuzumab deruxtecan (T-DXd) does not have any significant effect on real-world (rw) progression-free survival (PFS) or treatment-related toxicities among patients with metastatic breast cancer (MBC), as shown in a Singapore study.
Dose reduction does not limit efficacy of trastuzumab deruxtecan in MBC
01 Oct 2025
Long COVID symptoms may persist 3 years post-infection
01 Oct 2025
byAudrey Abella
One in five COVID-19 survivors experiences at least one unresolved symptom 3 years after the initial infection, a systematic review and meta-analysis reports.







